Resources from the same session
Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union
Presenter: Aurore Bergamasco
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Presenter: Martin Gutierrez
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions
Presenter: Pierre Vanden Borre
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Pancreatic neuroendocrine tumour (pNET) profiles in the NETwork! programme: clinic–enabled genomics for genomic-enabled clinical decisions
Presenter: Ben Lawrence
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Presentation
NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis
Presenter: Jonathan Strosberg
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
Presenter: Angela Lamarca
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
Presenter: Sara Pusceddu
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Invited discussant abstracts 427PD and 428PD
Presenter: Xavier Matias-Guiu
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Invited discussant abstracts 416O and 417O
Presenter: James Yao
Session: Endocrine and neuroendocrine tumours
Resources:
Presentation
Webcast
Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome
Presenter: Matthew Kulke
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract